Biotechnology in France
Published: August 2013 · Publisher: MarketLine
Biotechnology in France industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017).
- Description
- Companies Mentioned
- Table of Contents
- Ask a Question
Introduction
Biotechnology in France industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the France biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.
*The French biotechnology market had total revenues of $5.5bn in 2012, representing a compound annual growth rate (CAGR) of 8.6% between 2008 and 2012.
*Despite the continuing global economic uncertainties, the number of new firms created in the French life-science sector increased and funding has rebounded in 2012.
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 7.9% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $8.0bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in France
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in France
Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the France biotechnology market with five year forecasts
Macroeconomic indicators provide insight into general trends within the France economy
Key Questions Answered
What was the size of the France biotechnology market by value in 2012?
What will be the size of the France biotechnology market in 2017?
What factors are affecting the strength of competition in the France biotechnology market?
How has the market performed over the last five years?
What are the main segments that make up France's biotechnology market?
Biotechnology in France industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the France biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.
*The French biotechnology market had total revenues of $5.5bn in 2012, representing a compound annual growth rate (CAGR) of 8.6% between 2008 and 2012.
*Despite the continuing global economic uncertainties, the number of new firms created in the French life-science sector increased and funding has rebounded in 2012.
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 7.9% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $8.0bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in France
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in France
Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the France biotechnology market with five year forecasts
Macroeconomic indicators provide insight into general trends within the France economy
Key Questions Answered
What was the size of the France biotechnology market by value in 2012?
What will be the size of the France biotechnology market in 2017?
What factors are affecting the strength of competition in the France biotechnology market?
How has the market performed over the last five years?
What are the main segments that make up France's biotechnology market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
#N/A
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 14
New entrants 15
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
BioAlliance Pharma SA 19
bioMerieux SA 20
Merck & Co., Inc. 23
Transgene S.A. 26
Macroeconomic Indicators 29
Country Data 29
Appendix 31
Methodology 31
Industry associations 32
Related research 32
LIST OF TABLES
Table 1: France biotechnology market value: $ billion, 2008–12 8
Table 2: France biotechnology market category segmentation: $ billion, 2012 9
Table 3: France biotechnology market geography segmentation: $ billion, 2012 10
Table 4: France biotechnology market value forecast: $ billion, 2012–17 11
Table 5: BioAlliance Pharma SA: key facts 19
Table 6: bioMerieux SA: key facts 20
Table 7: bioMerieux SA: key financials ($) 21
Table 8: bioMerieux SA: key financials (€) 21
Table 9: bioMerieux SA: key financial ratios 21
Table 10: Merck & Co., Inc.: key facts 23
Table 11: Merck & Co., Inc.: key financials ($) 24
Table 12: Merck & Co., Inc.: key financial ratios 24
Table 13: Transgene S.A.: key facts 26
Table 14: Transgene S.A.: key financials ($) 27
Table 15: Transgene S.A.: key financial ratios 27
Table 16: France size of population (million), 2008–12 29
Table 17: France gdp (constant 2000 prices, $ billion), 2008–12 29
Table 18: France gdp (current prices, $ billion), 2008–12 29
Table 19: France inflation, 2008–12 30
Table 20: France consumer price index (absolute), 2008–12 30
Table 21: France exchange rate, 2008–12 30
LIST OF FIGURES
Figure 1: France biotechnology market value: $ billion, 2008–12 8
Figure 2: France biotechnology market category segmentation: % share, by value, 2012 9
Figure 3: France biotechnology market geography segmentation: % share, by value, 2012 10
Figure 4: France biotechnology market value forecast: $ billion, 2012–17 11
Figure 5: Forces driving competition in the biotechnology market in France, 2012 12
Figure 6: Drivers of buyer power in the biotechnology market in France, 2012 13
Figure 7: Drivers of supplier power in the biotechnology market in France, 2012 14
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology market in France, 2012 15
Figure 9: Factors influencing the threat of substitutes in the biotechnology market in France, 2012 17
Figure 10: Drivers of degree of rivalry in the biotechnology market in France, 2012 18
Figure 11: bioMerieux SA: revenues & profitability 22
Figure 12: bioMerieux SA: assets & liabilities 22
Figure 13: Merck & Co., Inc.: revenues & profitability 25
Figure 14: Merck & Co., Inc.: assets & liabilities 25
Figure 15: Transgene S.A.: revenues & profitability 28
Figure 16: Transgene S.A.: assets & liabilities 28
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 14
New entrants 15
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
BioAlliance Pharma SA 19
bioMerieux SA 20
Merck & Co., Inc. 23
Transgene S.A. 26
Macroeconomic Indicators 29
Country Data 29
Appendix 31
Methodology 31
Industry associations 32
Related research 32
LIST OF TABLES
Table 1: France biotechnology market value: $ billion, 2008–12 8
Table 2: France biotechnology market category segmentation: $ billion, 2012 9
Table 3: France biotechnology market geography segmentation: $ billion, 2012 10
Table 4: France biotechnology market value forecast: $ billion, 2012–17 11
Table 5: BioAlliance Pharma SA: key facts 19
Table 6: bioMerieux SA: key facts 20
Table 7: bioMerieux SA: key financials ($) 21
Table 8: bioMerieux SA: key financials (€) 21
Table 9: bioMerieux SA: key financial ratios 21
Table 10: Merck & Co., Inc.: key facts 23
Table 11: Merck & Co., Inc.: key financials ($) 24
Table 12: Merck & Co., Inc.: key financial ratios 24
Table 13: Transgene S.A.: key facts 26
Table 14: Transgene S.A.: key financials ($) 27
Table 15: Transgene S.A.: key financial ratios 27
Table 16: France size of population (million), 2008–12 29
Table 17: France gdp (constant 2000 prices, $ billion), 2008–12 29
Table 18: France gdp (current prices, $ billion), 2008–12 29
Table 19: France inflation, 2008–12 30
Table 20: France consumer price index (absolute), 2008–12 30
Table 21: France exchange rate, 2008–12 30
LIST OF FIGURES
Figure 1: France biotechnology market value: $ billion, 2008–12 8
Figure 2: France biotechnology market category segmentation: % share, by value, 2012 9
Figure 3: France biotechnology market geography segmentation: % share, by value, 2012 10
Figure 4: France biotechnology market value forecast: $ billion, 2012–17 11
Figure 5: Forces driving competition in the biotechnology market in France, 2012 12
Figure 6: Drivers of buyer power in the biotechnology market in France, 2012 13
Figure 7: Drivers of supplier power in the biotechnology market in France, 2012 14
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology market in France, 2012 15
Figure 9: Factors influencing the threat of substitutes in the biotechnology market in France, 2012 17
Figure 10: Drivers of degree of rivalry in the biotechnology market in France, 2012 18
Figure 11: bioMerieux SA: revenues & profitability 22
Figure 12: bioMerieux SA: assets & liabilities 22
Figure 13: Merck & Co., Inc.: revenues & profitability 25
Figure 14: Merck & Co., Inc.: assets & liabilities 25
Figure 15: Transgene S.A.: revenues & profitability 28
Figure 16: Transgene S.A.: assets & liabilities 28
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.